Carlo Incerti - Nov 18, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Director
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Nov 18, 2024
Transactions value $
-$330,660
Form type
4
Date filed
11/18/2024, 07:42 PM
Previous filing
May 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Options Exercise $143K +16.5K $8.69 16.5K Nov 18, 2024 Direct
transaction DYN Common Stock Sale -$474K -16.5K -100% $28.73 0 Nov 18, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock option (right to buy) Options Exercise $0 -16.5K -42.1% $0.00 22.7K Nov 18, 2024 Common Stock 16.5K $8.69 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.47 to $29.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F2 The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025.